anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a diagnostic result reporting method which can make a diagnosis based upon biological information measured by an expensive biological information measuring instrument without owning the expensive biological information measuring instrument and report the result of the diagnosis without imposing any burden on a patient.  <P>SOLUTION: The biological information that the patient has obtained at a biological information measuring institution 20 is stored on a server 24, which transmits the stored biological information of the patient to a doctor terminal device 18 of a doctor who diagnoses the patient. The doctor can generate a diagnosis result according to the set biological information, so the doctor need not own the expensive biological information measuring instrument 32. Further, the doctor sends the diagnosis result from the doctor terminal device 18 to the server 24. The server 24 stores the sent diagnosis result and sends the diagnosis result to the patient terminal device 14 according to a diagnosis result request signal from the patient terminal device 24. The patient, therefore, need not see the doctor to know the diagnosis result.  <P>COPYRIGHT: (C)2003,JPO
A vegtable oil fraction rich in non-tocolic, high-melting, unsaponifiable matter is prepared by the following steps: A vegetable oil having a slip melting point of not more thatn 30~C and a content of unsaponifiable matter of at least 0.5% by weight is hydrongenated to fully saturate the fatty acids of the glycerides and to reach a slip melting point of at least 57~C. To the hydrongenated oil is added from 1 to 75% by weight of the unhydrogenated starting oil or another oil having a slip melting poing of not more than 30~C  in order to act as a carrier and vehicle for the unsaponifiable matter. Then, a solvent is added to the oil mixture in a ratio between oil and solvent from 1:2 to 1:20, and the mixture is heated to transparency. The oil/-solvent-mixture is cooled in one or more steps to a final temperature in the range from -35 to+30~C, and the precipitated high-melting fraction(s) is (are) filtered off. The filtrate is desolventised, leaving a fraction rich in unsaponifiable matter. By this process very high concentrations of in particular the non-tocolic, higher melting unsaponifiables can be achieved, and the composition of the glyceridic part of the enriched fraction can betailored to specific applications. Also, a novel blood cholesterol-lowering effect of the unsaponifiable constituents from shea butter has been found.
In several studies with oral clonidine hydrochloride, a dose-dependent increase in the incidence and severity of spontaneous retinal degeneration was seen in albino rats treated for six months or longer. Tissue distribution studies in dogs and monkeys showed a concentration of clonidine in the choroid. 

In view of the retinal degeneration seen in rats, eye examinations were performed during clinical trials in 908 patients before, and periodically after, the start of clonidine therapy. In 353 of these 908 patients, the eye examinations were carried out over periods of 24 months or longer. Except for some dryness of the eyes, no drug-related abnormal ophthalmological findings were recorded and, according to specialized tests such as electroretinography and macular dazzle, retinal function was unchanged. 

In combination with amitriptyline, clonidine hydrochloride administration led to the development of corneal lesions in rats within 5 days.
An examination assisting apparatus capable of preventing an error in a registration operation performed by an user for associating photographed image data of an affected area of a patient with patient information. A user acquires patient information by reading a patient identifier and holds the same in a storage medium, and generates and stores photographed image data in association with the patient information stored in the storage medium. Walking information of a walk of the user is acquired. Notification to the user is performed based on the walking information. Photographing by an image capturing operation is stopped based on the walking information. The patient information is deleted from the storage medium based on an operation by the user in response to the notification. The notification is terminated in a case where the patient information is deleted from the storage medium.
Interventions will be selected by the ADVANCE Steering Committee and will be rapidly deployed without additional effort on the part of front-line staff at four distinct levels: patient, provider, practice and prison level. Interventions will be tested one at a time in an iterative process. A participatory, assets-based framework will be used to identify acceptable and feasible strategies to improve vaccine acceptance. Each round of testing will include 1 month of preparation by the steering committee,12-week intervention period, and 2 months for analysis and rapid dissemination.
PROBLEM TO BE SOLVED: To obtain an antibody capable of inhibiting the PDGF(platelet derived growth factor) BB lag phase of cells expressing human β-PDGF in a defined concentration to a higher extent than a specific value and useful e.g. for the therapy and diagnosis of adult dyspnea syndrome-related pulmonary fibrosis or the like. SOLUTION: This antibody can specifically bind to a β-PDGF receptor not existing in the fifth extracellular Ig-like domain and inhibits the PDGF BB lag phase of cells expressing β-PDGF in an antibody concentration of 10 μg/mL to an extent of >80%. The antibody preferably inhibits the binding of the PDGF BB to cells expressing a β-PDGF receptor or binds to the extracellular Ig-like domain of a β-PDGF receptor. A composition comprising the antibody and a medicinally permissible excipient preferably is prepared. The daily dosage level of the antibody preferably is from 0.1 mg/kg to 10.0 mg/kg.
Measurements of dynamic changes in oxygen uptake (VO2 kinetics) during recovery from exercise may describe regulatory control of oxygen transport and utilization and have greater reliability and less inherent risk than assessment of maximal oxygen uptake (VO2max) in patients for whom exercise is limited by pain, excessive fatigue, dyspnea and motivation. The purpose of this pilot study is to evaluate the effect of exercise intensity on the time constant describing changes in VO2 (tauVO2) during recovery from one minute of constant work rate exercise. Five normal healthy volunteers ages 18 and older will perform a progressive maximal aerobic exercise test, using a cycle ergometer, to determine VO2max and lactate threshold (LT) estimated by gas exchange. Each subject will also complete a series of maximal constant work rate tests and submaximal constant work rate tests at 80% LT and 50% of the difference between LT and VO2max (50% delta). Breath by breath variability and VO2 span will be used to determine the number of constant work rate test repetitions, for each subject for each exercise intensity, needed to establish confidence in tauVO2. A mean response profile of VO2 recovery kinetics for each exercise intensity will be analyzed using non-linear regression to determine tauVO2. To examine the effect of exercise intensity on tauVO2, one way analysis of variance will be used to determine whether differences exist among maximal and submaximal (80% LT and 50% delta) time constants. We hypothesize that there will be no significant differences among time constants for VO2 during recovery from maximal and submaximal constant work rate exercise lasting one minute. The results of this study are expected to provide increased understanding of the measurement of VO2 kinetics during recovery.
Epilepsy is defined by the abrupt emergence of harmful seizures, but the nature of these regime shifts remains enigmatic. From the perspective of dynamical systems theory, such critical transitions occur upon inconspicuous perturbations in highly interconnected systems and can be modeled as mathematical bifurcations between alternative regimes. The predictability of critical transitions represents a major challenge, but the theory predicts the appearance of subtle dynamical signatures on the verge of instability. Whether such dynamical signatures can be measured before impending seizures remains uncertain. Here, we verified that predictions on bifurcations applied to the onset of hippocampal seizures, providing concordant results from in silico modeling, optogenetics experiments in male mice and intracranial EEG recordings in human patients with epilepsy. Leveraging pharmacological control over neural excitability, we showed that the boundary between physiological excitability and seizures can be inferred from dynamical signatures passively recorded or actively probed in hippocampal circuits. Of importance for the design of future neurotechnologies, active probing surpassed passive recording to decode underlying levels of neural excitability, notably when assessed from a network of propagating neural responses. Our findings provide a promising approach for predicting and preventing seizures, based on a sound understanding of their dynamics.
Athlete's heart is generally regarded as a physiological adaptation to regular training, with specific morphological and functional alterations in the cardiovascular system. Development of the noninvasive imaging techniques over the past several years enabled better assessment of cardiac remodeling in athletes, which may eventually mimic certain pathological conditions with the potential for sudden cardiac death, or disease progression. The current literature provides a compelling overview of the available methods that target the interrelation of prolonged exercise with cardiac structure and function. However, this data stems from scientific studies that included mostly male athletes. Despite the growing participation of females in competitive sport meetings, little is known about the long-term cardiac effects of repetitive training in this population. There are several factors-biochemical, physiological and psychological, that determine sex-dependent cardiac response. Herein, the aim of this review was to compare cardiac adaptation to endurance exercise in male and female athletes with the use of electrocardiographic, echocardiographic, and biochemical examination, to determine the sex-specific phenotypes, and to improve the healthcare providers' awareness of cardiac remodeling in athletes. Finally, we discuss the possible exercise-induced alternations that should arouse suspicion of pathology and be further evaluated.
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group study with two secukinumab dose regimens in approximately 360 PMR patients who had recently relapsed. The study consists of: screening (up to 6 weeks); treatment period (52 weeks, with last IMP administration at 48 weeks, active drug or placebo) in combination with prednisone tapered over 24 weeks; treatment-free follow-up (up to 24 weeks). Adult males and females of at least 50 years of age with a recent PMR relapse (within 12 weeks from Baseline) will be included. Dosing will be once every week for the first 4 weeks, and once every 4 weeks thereafter via pre-filled syringe.

The primary objective is to demonstrate the efficacy of secukinumab 300 mg subcutaneously in combination with a 24-week glucocorticoid (GC) taper regimen compared with placebo with respect to the proportion of patients in sustained remission at Week 52. Primary secondary objectives are to assess difference in proportion of patients achieving complete sustained remission at Week 52, adjusted annual cumulative GC dose and time to first use of escape treatment or rescue treatment through Week 52. Key safety data will be collected, along with Patient Reported Outcomes.
The present invention provides a use of Allium cepa cv. extract and the effective compound of it for eye protection. The Allium cepa cv. extract can effectively reduce the apoptosis of the retinal cells irradiated by UV light, and reduce the active oxides and oxidative stress generated in the retinal cells exposed by the blue light to prevent retinal cells exposed to UV light or blue light from being damaged. The Allium cepa cv. extracts is prepared by extracting Allium cepa cv. using water, alcohols, or mixtures of water and alcohols as solvents, and the Allium cepa cv. extract contains an effective component of quercetin-3,4'-diglucoside and/or tryptophan.
This is an acute study to test the ability of a custom external device (MAX-SRS) to sense atrial rhythms, determine when AF is present and deliver spatial resynchronization therapy (SRT) to terminate AF.

Patients will have commercially available diagnostic electrophysiologic catheters placed in the coronary sinus and on the heart. The catheters will be connected to the MAX-SRS. If AF is not present, standard pacing measures will be used to induce AF. Once \> 1 minute of AF is recorded, the MAX-SRS will be activated to sense the rhythm and deliver SRT pacing to terminate the AF. Up to five SRT deliveries using the same or different SRT algorithms will be attempted. After the first successful termination of AF or after five SRT attempts the study is complete for each patient. Diagnostic catheters will be removed after the conclusion of the SRT pacing study.
To use supplemental oxygen to decrease peripheral chemoreceptor activity in patients with SCI and central SDB. In addition, perform a repeat evaluation after treatment with supplemental oxygen or sham O2 for 6 weeks to determine if correction of chronic intermittent hypoxia, which mitigates sensory LTF, results in decreased propensity to central apnea.
pregnancy Category B. There are no adequate and well-controlled studies of valacyclovir hydrochloride or acyclovir in pregnant women. Based on prospective pregnancy registry data on 749 pregnancies, the overall rate of birth defects in infants exposed to acyclovir in-utero appears similar to the rate for infants in the general population. Valacyclovir hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.  
A prospective epidemiologic registry of acyclovir use during pregnancy was established in 1984 and completed in April 1999. There were 749 pregnancies followed in women exposed to systemic acyclovir during the first trimester of pregnancy resulting in 756 outcomes. The occurrence rate of birth defects approximates that found in the general population. However, the small size of the registry is insufficient to evaluate the risk for less common defects or to permit reliable or definitive conclusions regarding the safety of acyclovir in pregnant women and their developing fetuses.  
Animal reproduction studies performed at oral doses that provided up to 10 and 7 times the human plasma levels during the period of major organogenesis in rats and rabbits, respectively, revealed no evidence of teratogenicity.
Liver transplantation is the curative therapy of choice for patients with early-stage HCC. Locoregional therapies are often employed as a bridge to reduce the risk of waitlist dropout; however, their association with posttransplant outcomes is unclear. We conducted a systematic review using Ovid MEDLINE and EMBASE to identify studies published between database inception and August 2, 2023, which reported posttransplant recurrence-free survival and overall survival among patients transplanted for HCC within Milan criteria, stratified by receipt of bridging therapy. Pooled HRs were calculated for each outcome using the DerSimonian and Laird method for a random-effects model. We identified 38 studies, including 19,671 patients who received and 20,148 patients who did not receive bridging therapy. Bridging therapy was not associated with significant differences in recurrence-free survival (pooled HR: 0.91, 95% CI: 0.77-1.08; I2 =39%) or overall survival (pooled HR: 1.09, 95% CI: 0.95-1.24; I2 =47%). Results were relatively consistent across subgroups, including geographic location and study period. Studies were discordant regarding the differential strength of association by pretreatment tumor burden and pathologic response, but potential benefits of locoregional therapy were mitigated in those who received 3 or more treatments. Adverse events were reported in a minority of studies, but when reported occurred in 6%-15% of the patients. Few studies reported loss to follow-up and most had a risk of residual confounding. Bridging therapy is not associated with improvements in posttransplant recurrence-free or overall survival among patients with HCC within Milan criteria. The risk-benefit ratio of bridging therapy likely differs based on the risk of waitlist dropout.
IV bolus of 150 mg/kg L-citrulline at the initiation of bypass, followed by L-citrulline (200 μmol/L) addition to the filtration or hemoconcentration replacement fluid used during bypass. Plus L-citrulline (20 mg/kg) bolus 30 minutes after decannulation from bypass, immediately followed by 9 mg/kg/h continuous L-citrulline infusion for 48 hours.
PROBLEM TO BE SOLVED: To obtain tablets having good color dispersion and development without causing them to be broken by tabletting pressure by dispersing carotenoid pigment crystals in a state not dissolved in fat and oil in a water-soluble material comprising an emulsifier, an excipient and an antioxidant, pulverizing the crystals with a grinder to form a dry powder and using this powder. SOLUTION: Although not particularly limited, the carotenoid pigment is selected among β-carotene, canthaxanthin, β-apo-8'-carotenal, leupin, lutein, etc. The emulsifier is exemplified by a food material having emulsion stabilizing effect such as a sucrose fatty acid ester, lecitin, a glycerol fatty acid ester, soybean saponin, arabic gum, pectin, dextrin or casein. The excipient used is a food processing material such as dextrin or starch. The antioxidant used is ascorbic acid or cetechin having antioxidant effect on fat and oil. The comminuted carotenoid pigment crystals have a particle diameter of 2μm or below, desirably 0.5μm or below.
FIELD: food industry. ^ SUBSTANCE: this invention covers food for 0-36 month aged infants. A composition comprising free amino acids as a single source of protein, source of fat acids comprising long-chain polyunsaturated fatty acids (LCPUFA), source of carbonhydrates comprising assimilable and non-assimilable carbonhydrates and bifidus bacteria was proposed for treatment of the patients suffering from tormina, astriction, snivel, sniffle, vomit, diarrhea, feces cruentae, mucus in defecation, spots, eczema, gastroesophageal reflux, eosinophilic esophagitis or asthma, allergy for cow milk and/or intolerance to dietary protein, and/or infections. Herewith, non-assimilable carbonhydrates are chosen from milk protein-free source, and bifidus bacteria are dietary protein-free, and the whole composition is essentially intact protein-free. Besides, assimilable carbonhydrate component contains less than 2 mass percent of lactose from overall assimilable carbonhydrates. Fat component includes 0.1-5 mass percent of LCPUFA from overall fat acids content. As an alternative, this composition is applied for stimulation of immune system maturation of the infants suffering from atopic diseases. ^ EFFECT: improvement of infant health without risks of adverse allergic reaction. ^ 25 cl, 2 dwg, 3 tbl, 1 ex
BACKGROUND AND AIMS: Italy has the greatest burden of hepatitis C virus (HCV) infection in Western Europe. The screening strategy represents a crucial prevention tool to achieve HCV elimination in Italy. We evaluated the cost-consequences of different screening strategies for the diagnosis of HCV active infection in the birth cohort 1948-1968 to achieve the HCV elimination goal.
METHODS: We designed a probabilistic model to estimate the clinical, and economic outcomes of different screening coverage uptakes, considering the direct costs of HCV management according to each liver fibrosis stage, in the Italian context. A decision probabilistic tree simulates 4 years of HCV testing of the 1948-1968 general population birth cohort, (15,485,565 individuals to be tested) considering different coverage rates. A No-screening scenario was compared with two alternative screening scenarios that represented different coverage rates each year: (1) Incremental approach (coverage rates equal to 5%, 10%, 30%, and 50% at years 1, 2, 3, and 4, respectively) and (2) Fast approach (50% coverage rate at years 1, 2, 3 and 4). Overall 106,200 cases were previously estimated to have an HCV active infection. A liver disease progression Markov model was considered for an additional 6 years (horizon-time 10 years).
RESULTS: The highest increased number of deaths and clinical events are reported for the No-screening scenario (21,719 cumulative deaths at the end of ten years; 10,148 cases with HCC and/or 7618 cases with Decompensated Cirrhosis). Following the Fast-screening scenario, the reductions in clinical outcomes and deaths were higher compared with No-screening and Incremental-screening. At ten years time horizon, less than 5696 liver deaths (PSA CI95%: - 3873 to 7519), 3,549 HCC (PSA CI95%: - 2413 to 4684) and less than 3005 liver decompensations (PSA CI 95%: - 2104 to 3907) were estimated compared with the Incremental-scenario. The overall costs of the Fast-screening, including the costs of the DAA and liver disease management of the infected patients for 10 years, are estimated to be € 43,107,543 more than no-investment in screening and € 62,289,549 less compared with the overall costs estimated by the Incremental-scenario.
CONCLUSION: It is necessary to guarantee dedicated funds and efficiency of the system for the cost-efficacious screening of the 1948-1968 birth cohort in Italy. A delay in HCV diagnosis and treatment in the general population, yet not addressed for the HCV free-of-charge screening, will have important clinical and economic consequences in Italy.